285 related articles for article (PubMed ID: 34365471)
21. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast.
Rathore AS; Kumar S; Konwar R; Makker A; Negi MP; Goel MM
Indian J Med Res; 2014 Sep; 140(3):361-9. PubMed ID: 25366203
[TBL] [Abstract][Full Text] [Related]
22. Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer.
Kuwahara T; Hazama S; Suzuki N; Yoshida S; Tomochika S; Nakagami Y; Matsui H; Shindo Y; Kanekiyo S; Tokumitsu Y; Iida M; Tsunedomi R; Takeda S; Yoshino S; Okayama N; Suehiro Y; Yamasaki T; Fujita T; Kawakami Y; Ueno T; Nagano H
Br J Cancer; 2019 Oct; 121(8):659-665. PubMed ID: 31488881
[TBL] [Abstract][Full Text] [Related]
23. Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma.
Han S; Zhang C; Li Q; Dong J; Liu Y; Huang Y; Jiang T; Wu A
Br J Cancer; 2014 May; 110(10):2560-8. PubMed ID: 24691423
[TBL] [Abstract][Full Text] [Related]
24. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.
Cimino-Mathews A; Ye X; Meeker A; Argani P; Emens LA
Hum Pathol; 2013 Oct; 44(10):2055-63. PubMed ID: 23701942
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of a tumor-infiltrating lymphocyte subtype in triple negative cancer of the breast.
Jamiyan T; Kuroda H; Yamaguchi R; Nakazato Y; Noda S; Onozaki M; Abe A; Hayashi M
Breast Cancer; 2020 Sep; 27(5):880-892. PubMed ID: 32222891
[TBL] [Abstract][Full Text] [Related]
26. CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer.
Plevova P; Cerna D; Balcar A; Foretova L; Zapletalova J; Silhanova E; Curik R; Dvorackova J
Neoplasma; 2010; 57(4):325-32. PubMed ID: 20429623
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
28. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast.
Leong PP; Mohammad R; Ibrahim N; Ithnin H; Abdullah M; Davis WC; Seow HF
Immunol Lett; 2006 Feb; 102(2):229-36. PubMed ID: 16246429
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy.
Tsiatas M; Kalogeras KT; Manousou K; Wirtz RM; Gogas H; Veltrup E; Zagouri F; Lazaridis G; Koutras A; Christodoulou C; Pentheroudakis G; Petraki C; Bafaloukos D; Pectasides D; Kosmidis P; Samantas E; Karanikiotis C; Papakostas P; Dimopoulos MA; Fountzilas G
Cancer Med; 2018 Oct; 7(10):5066-5082. PubMed ID: 30240146
[TBL] [Abstract][Full Text] [Related]
30. Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.
Wen WX; Leong CO
PLoS One; 2019; 14(4):e0215381. PubMed ID: 31022191
[TBL] [Abstract][Full Text] [Related]
31. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
32. An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer.
Mahmoud SM; Paish EC; Powe DG; Macmillan RD; Lee AH; Ellis IO; Green AR
Breast Cancer Res Treat; 2011 May; 127(1):99-108. PubMed ID: 20556505
[TBL] [Abstract][Full Text] [Related]
33. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.
; Goode EL; Block MS; Kalli KR; Vierkant RA; Chen W; Fogarty ZC; Gentry-Maharaj A; Tołoczko A; Hein A; Bouligny AL; Jensen A; Osorio A; Hartkopf A; Ryan A; Chudecka-Głaz A; Magliocco AM; Hartmann A; Jung AY; Gao B; Hernandez BY; Fridley BL; McCauley BM; Kennedy CJ; Wang C; Karpinskyj C; de Sousa CB; Tiezzi DG; Wachter DL; Herpel E; Taran FA; Modugno F; Nelson G; Lubiński J; Menkiszak J; Alsop J; Lester J; García-Donas J; Nation J; Hung J; Palacios J; Rothstein JH; Kelley JL; de Andrade JM; Robles-Díaz L; Intermaggio MP; Widschwendter M; Beckmann MW; Ruebner M; Jimenez-Linan M; Singh N; Oszurek O; Harnett PR; Rambau PF; Sinn P; Wagner P; Ghatage P; Sharma R; Edwards RP; Ness RB; Orsulic S; Brucker SY; Johnatty SE; Longacre TA; Ursula E; McGuire V; Sieh W; Natanzon Y; Li Z; Whittemore AS; Anna A; Staebler A; Karlan BY; Gilks B; Bowtell DD; Høgdall E; Candido dos Reis FJ; Steed H; Campbell IG; Gronwald J; Benítez J; Koziak JM; Chang-Claude J; Moysich KB; Kelemen LE; Cook LS; Goodman MT; García MJ; Fasching PA; Kommoss S; Deen S; Kjaer SK; Menon U; Brenton JD; Pharoah PDP; Chenevix-Trench G; Huntsman DG; Winham SJ; Köbel M; Ramus SJ
JAMA Oncol; 2017 Dec; 3(12):e173290. PubMed ID: 29049607
[TBL] [Abstract][Full Text] [Related]
34. Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes.
Sobral-Leite M; Salomon I; Opdam M; Kruger DT; Beelen KJ; van der Noort V; van Vlierberghe RLP; Blok EJ; Giardiello D; Sanders J; Van de Vijver K; Horlings HM; Kuppen PJK; Linn SC; Schmidt MK; Kok M
Breast Cancer Res; 2019 Aug; 21(1):90. PubMed ID: 31391067
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells.
Diederichsen AC; Hjelmborg Jv; Christensen PB; Zeuthen J; Fenger C
Cancer Immunol Immunother; 2003 Jul; 52(7):423-8. PubMed ID: 12695859
[TBL] [Abstract][Full Text] [Related]
36. Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer.
Takada K; Kashiwagi S; Goto W; Asano Y; Takahashi K; Takashima T; Tomita S; Ohsawa M; Hirakawa K; Ohira M
J Transl Med; 2018 Apr; 16(1):86. PubMed ID: 29615076
[TBL] [Abstract][Full Text] [Related]
37. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.
Li F; Sun Y; Huang J; Xu W; Liu J; Yuan Z
Cancer Med; 2019 Dec; 8(17):7330-7344. PubMed ID: 31631566
[TBL] [Abstract][Full Text] [Related]
38. Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families.
Eerola H; Heinonen M; Heikkilä P; Kilpivaara O; Tamminen A; Aittomäki K; Blomqvist C; Ristimäki A; Nevanlinna H
Breast Cancer Res; 2008; 10(1):R17. PubMed ID: 18275599
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancer.
Kinoshita T; Muramatsu R; Fujita T; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Kudo-Saito C; Hayashi Y; Kamiyama I; Ohtsuka T; Asamura H; Kawakami Y
Ann Oncol; 2016 Nov; 27(11):2117-2123. PubMed ID: 27502728
[TBL] [Abstract][Full Text] [Related]
40. Immune characterization of breast cancer metastases: prognostic implications.
Dieci MV; Tsvetkova V; Orvieto E; Piacentini F; Ficarra G; Griguolo G; Miglietta F; Giarratano T; Omarini C; Bonaguro S; Cappellesso R; Aliberti C; Vernaci G; Giorgi CA; Faggioni G; Tasca G; Conte P; Guarneri V
Breast Cancer Res; 2018 Jun; 20(1):62. PubMed ID: 29929548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]